- Home
- GITS vs LIXT Comparison
GITS vs LIXT Comparison
Compare GITS & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GITS
- LIXT
- Stock Information
- Founded
- GITS 2018
- LIXT 2005
- Country
- GITS South Korea
- LIXT United States
- Employees
- GITS N/A
- LIXT N/A
- Industry
- GITS
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- GITS
- LIXT Health Care
- Exchange
- GITS Nasdaq
- LIXT Nasdaq
- Market Cap
- GITS 4.8M
- LIXT 4.1M
- IPO Year
- GITS N/A
- LIXT N/A
- Fundamental
- Price
- GITS $1.09
- LIXT $1.19
- Analyst Decision
- GITS
- LIXT
- Analyst Count
- GITS 0
- LIXT 0
- Target Price
- GITS N/A
- LIXT N/A
- AVG Volume (30 Days)
- GITS 76.9K
- LIXT 31.7K
- Earning Date
- GITS 11-20-2024
- LIXT 03-24-2025
- Dividend Yield
- GITS N/A
- LIXT N/A
- EPS Growth
- GITS N/A
- LIXT N/A
- EPS
- GITS N/A
- LIXT N/A
- Revenue
- GITS N/A
- LIXT N/A
- Revenue This Year
- GITS N/A
- LIXT N/A
- Revenue Next Year
- GITS N/A
- LIXT N/A
- P/E Ratio
- GITS N/A
- LIXT N/A
- Revenue Growth
- GITS 85.47
- LIXT N/A
- 52 Week Low
- GITS $0.10
- LIXT $1.02
- 52 Week High
- GITS $5.06
- LIXT $3.80
- Technical
- Relative Strength Index (RSI)
- GITS N/A
- LIXT 41.29
- Support Level
- GITS N/A
- LIXT $1.18
- Resistance Level
- GITS N/A
- LIXT $1.31
- Average True Range (ATR)
- GITS 0.00
- LIXT 0.10
- MACD
- GITS 0.00
- LIXT 0.03
- Stochastic Oscillator
- GITS 0.00
- LIXT 43.24
About GITS Global Interactive Technologies Inc. Common Stock
Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.